Geo-Young announced today that it has signed a Memorandum of Understanding with UBC Korea to distribute Bimzelx.

Under the agreement, Geo-Young will carry out the entire distribution process from storage to supply of Bimzelx.

Bimzelx is a treatment for plaque psoriasis that simultaneously and directly targets and inhibits interleukin 17A and 17F (IL-17A·IL-17F), protein immunomodulators that drive inflammation in psoriatic disease. 

On August 29, Bimzelx the Ministry of Food and Drug Safety approved Bimzelx as a treatment for adult patients with moderate-to-severe psoriasis who require phototherapy or systemic therapy. Through this distribution agreement, Geo-Young